 |
BioWorld-Insight-2002-06-10
'Back To The Future': Market's Year Of Living Dangerously
'Back To The Future': Market's Year Of Living Dangerously
Second-quarter earnings disappointments, recent clinical trial failures and investors' apparent refusal to credit any of the good news have pushed biotechnology valuations down to levels not seen since the mid-1990s. (BioWorld Financial Watch)